Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact

JCI Insight Editorial Board
potential first-tier conflicts of interest

Updated February 17, 2023

Go to JCI Insight's conflict-of-interest policy

 

Almirall (J.E. Gudjonsson)

Arcus Biosciences (Y.M. Shah)

Arrowhead (A.P. Lieberman)

Arvinas (A.P. Lieberman)

BMS (J.E. Gudjonsson)

CStone (W. Zou)

Eli Lilly (J.E. Gudjonsson)

Galderma (J.E. Gudjonsson)

Intergalactic (W. Zou)

Janssen (J.E. Gudjonsson)

Johnson & Johnson (D. Martin)

Kyowa Kirin (J.E. Gudjonsson)

NextCure (W. Zou)

NGM Bio (W. Zou)

ONL Therapeutics (A. Tai)

Opsidio LLC (N. W. Lukacs)

Pfizer (D. Martin)

Prometheus (J.E. Gudjonsson)

Roivant (W. Zou)

 

Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts